Although CDK4/6 inhibitors for breast cancer have achieved remarkable clinical success12,26,27, the specific mechanisms of how CDK4 and CDK6 affect tumor micro-environment (TME) and anti-tumor immunity are still poorly understood. This evidence concerns the gene CDK4 and breast cancer.